R&D Symposium on Antibody Conjugates

Johnson & Johnson in Belgium invites you to our one-day symposium to explore exciting advances in the discovery and development of antibody conjugates:antibody-drug conjugates and radioligand therapies. From next-generation ADCs and RLTs, innovation in ADC/RLT design and development to clinical studies, we will discuss success stories and future perspectives with leaders from both academia and industry.

• When?         Thursday, June 19, 2025, from 9 AM – 5.30 PM 
• Where?        Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium  
• For whom?  Researchers, clinicians, and industry leaders active in the antibody conjugate space   

Our confirmed speakers: Alain Beck (Pierre Fabre Laboratories, France), Robin Carr (Myricx Bio, United Kingdom), David Planchard (Institut Gustave Roussy, France), Philipp R. Spycher (Araris Biotech AG, Switzerland), Marc Robillard (Tagworks Pharmaceuticals, Netherlands), David Klauber (AstraZeneca, United Kingdom), Ken Herrmann (University of Duisburg-Essen, Germany), Danielle Park (Novartis, Switzerland), Anne-Marie Dingemans (Erasmus University Rotterdam, Netherlands), Gunhild von Amsberg (University of Hamburg, Germany), Josh Lauring (J&J, USA)and Jacqueline Kinyamu-Akunda (J&J, USA).

Registration is free, but seats are limited. Register now to secure your spot.

Should you have any questions related to this event, please contact Cindy Verachtert (cveracht@its.jnj.com) & Rebecca Valetitsch (rvaletit@its.jnj.com).

More info and registration, please click here.